溶血性贫血:补体介导红细胞破坏机制

高清妍; 张凤奎

doi:10.13201/j.issn.1004-2806.2016.11.002

溶血性贫血:补体介导红细胞破坏机制

高清妍,
张凤奎^,

- 中国医学科学院北京协和医学院血液学研究所血液病医院(天津, 300020)

详细信息

通讯作者: 张凤奎,E-mail:zhfk@hotmail.com

中图分类号: R556.6

收稿日期: 2016-07-21

Hemolytic anemia: complement mediated red cell destruction

GAO Qingyan,
ZHANG Fengkui^,

More Information

Corresponding author: ZHANG Fengkui, E-mail: zhfk@hotmail.com

Received Date: 21 July 2016

摘要

- 贫血,溶血性 /
- 补体
- hemolytic anemia /
- complement

HTML全文

参考文献(35)

[1]	Varela JC,Tomlinson S.Complement:an overview for the clinician[J].Hematol Oncol Clin North Am,2015,29:409-427.
[2]	Walport MJ.Complement.First of two parts[J].N Engl J Med,2001,344:1058-1066.
[3]	Harboe M,Mollnes TE.The alternative complement pathway revisited[J].J Cell Mol Med,2008,12:1074-1084.
[4]	Brodsky RA.Complement in hemolytic anemia[J].Blood,2015,126:2459-2465.
[5]	Dezern AE,Brodsky RA.Paroxysmal nocturnal hemoglobinuria:a complement-mediated hemolytic anemia[J].Hematol Oncol Clin North Am,2015,29:479-494.
[6]	Hochsmann B,Schrezenmeier H.Congenital CD59 deficiency[J].Hematol Oncol Clin North Am,2015,29:495-507.
[7]	Brodsky RA.Paroxysmal nocturnal hemoglobinuria[J].Blood,2014,124:2804-2811.
[8]	Luzzatto L.Recent advances in the pathogenesis and treatment of paroxysmal nocturnal hemoglobinuria[J].F1000Res,2016,5:F1000 Faculty Rev-209.
[9]	Fujita M,Kinoshita T.GPI-anchor remodeling:potential functions of GPI-anchors in intracellular trafficking and membrane dynamics[J].Biochim Biophys Acta,2012,1821:1050-1058.
[10]	Lin Z,Schmidt CQ,Koutsogiannaki S,et al.Complement C3dg-mediated erythrophagocytosis:implications for paroxysmal nocturnal hemoglobinuria[J].Blood,2015,126:891-894.
[11]	Risitano AM,Notaro R,Marando L,et al.Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab[J].Blood,2009,113:4094-4100.
[12]	Hill A,Rother RP,Arnold L,et al.Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization[J].Haematologica,2010,95:567-573.
[13]	Rondelli T,Risitano AM,Peffault de Latour R,et al.Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria[J].Haematologica,2014,99:262-266.
[14]	Nishimura J,Yamamoto M,Hayashi S,et al.Genetic variants in C5 and poor response to eculizumab[J].N Engl J Med,2014,370:632-639.
[15]	Berentsen S,Sundic T.Red blood cell destruction in autoimmune hemolytic anemia:role of complement and potential new targets for therapy[J].Biomed Res Int,2015,2015:363278.
[16]	Packman CH.Hemolytic anemia due to warm autoantibodies[J].Blood Rev,2008,22:17-31.
[17]	Sokol RJ,Booker DJ,Stamps R,et al.IgA red cell autoantibodies and autoimmune hemolysis[J].Transfusion,1997,37:175-181.
[18]	Randen U,Troen G,Tierens A,et al.Primary cold agglutinin-associated lymphoproliferative disease:a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma[J].Haematologica,2014,99:497-504.
[19]	Berentsen S,Ulvestad E,Langholm R,et al.Primary chronic cold agglutinin disease:a population based clinical study of 86 patients[J].Haematologica,2006,91:460-466.
[20]	Petz LD.Cold antibody autoimmune hemolytic anemias[J].Blood Rev,2008,22:1-15.
[21]	Shanbhag S,Spivak J.Paroxysmal cold hemoglobinuria[J].Hematol Oncol Clin North Am,2015,29:473-478.
[22]	Shapiro R,Chin-Yee I,Lam S.Eculizumab as a bridge to immunosuppressive therapy in severe cold agglutinin disease of anti-Pr specificity[J].Clin Case Rep,2015,3:942-944.
[23]	Roth A,Huttmann A,Rother RP,et al.Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease[J].Blood,2009,113:3885-3886.
[24]	Shi J,Rose EL,Singh A,et al.TNT003,an inhibitor of the serine protease C1s,prevents complement activation induced by cold agglutinins[J].Blood,2014,123:4015-4022.
[25]	Wouters D,Stephan F,Strengers P,et al.C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia[J].Blood,2013,121:1242-1244.
[26]	Kavanagh D,Raman S,Sheerin NS.Management of hemolytic uremic syndrome[J].F1000Prime Rep,2014,6:119.
[27]	Sperati CJ,Moliterno AR.Thrombotic microangiopathy:focus on atypical hemolytic uremic syndrome[J].Hematol Oncol Clin North Am,2015,29:541-559.
[28]	Turner N,Sartain S,Moake J.Ultralarge von Willebrand factor-induced platelet clumping and activation of the alternative complement pathway in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndromes[J].Hematol Oncol Clin North Am,2015,29:509-524.
[29]	Keir LS.Shiga toxin associated hemolytic uremic syndrome[J].Hematol Oncol Clin North Am,2015,29:525-539.
[30]	Chua JS,Baelde HJ,Zandbergen M,et al.Complement factor C4d is a common denominator in thrombotic microangiopathy[J].J Am Soc Nephrol,2015,26:2239-2247.
[31]	Noris M,Caprioli J,Bresin E,et al.Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype[J].Clin J Am Soc Nephrol,2010,5:1844-1859.
[32]	Fakhouri F,Hourmant M,Campistol JM,et al.Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome:a single-arm,open-label trial[J].Am J Kidney Dis,2016,68:84-93.
[33]	Legendre CM,Licht C,Muus P,et al.Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome[J].N Engl J Med,2013,368:2169-2181.
[34]	Simmons DP,Savage WJ.Hemolysis from ABO incompatibility[J].Hematol Oncol Clin North Am,2015,29:429-443.
[35]	Risitano AM.Current and future pharmacologic complement inhibitors[J].Hematol Oncol Clin North Am,2015,29:561-582.